ERIS Lifescience
Drug Manufacturers - Specialty & Generic · ERIS
Mid CapHealthcareHigh Growth
Amit Bakshi
Chairman and Managing Director · Visionary
Company DNA
Founder-Centric
About
ERIS Lifescience is a Mid Cap company in the Healthcare sector, listed on NSE as ERIS. With a market cap of ₹18K Cr and revenue of ₹3K Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Strong influence of CMD Amit Bakshi; typical of rapidly scaled promoter-led pharma companies in India. Its strategic mandate: Following recent acquisitions, the company must focus on expanding its specialized portfolio and integrating new therapeutic segments.
FAQ
What kind of company is ERIS Lifescience?
ERIS Lifescience is a Mid Cap Healthcare company (ERIS) in the High Growth phase with a market cap of ₹18K Cr. It is classified as Founder-Centric in culture.
What is ERIS Lifescience's culture and work environment like?
ERIS Lifescience has a Founder-Centric culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Strong influence of CMD Amit Bakshi; typical of rapidly scaled promoter-led pharma companies in India.
Who leads ERIS Lifescience?
ERIS Lifescience is led by Amit Bakshi (Chairman and Managing Director), a Visionary leader with 30 years of experience.
What are ERIS Lifescience's financials?
ERIS Lifescience reported revenue of ₹3K Cr in FY25 with a 5-year revenue CAGR of 29.5%. Operating margin: 24.4%. Market cap: ₹18K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleHigh Growth
Strong influence of CMD Amit Bakshi; typical of rapidly scaled promoter-led pharma companies in India.
Mandate
Following recent acquisitions, the company must focus on expanding its specialized portfolio and integrating new therapeutic segments.
Following recent acquisitions, the company must focus on expanding its specialized portfolio and integrating new therapeutic segments.
Financials
Revenue FY25₹3K Cr
PAT FY25₹352 Cr
Rev CAGR 5Y29.5%
OPM24.4%
NPM12.2%
ROE12.3%
ROCE12.4%
P/E41.8
Fwd P/E26.2
P/B5.8
D/E68.2
Mkt Cap₹18K Cr
Promoter68%
Institutional21.9%
Similar Culture
Could You Lead ERIS Lifescience?
Take the Genome Benchmark →